Compass Therapeutics posts Phase 2 results for CTX-009 in metastatic colorectal cancer trial
Results were first posted for the completed COMPANION-003 study of CTX-009 in previously treated metastatic colorectal cancer patients.
Compass Therapeutics had one notable update this week, tied to its CTX-009 colorectal cancer study.
- The Phase 2 study, NCT05513742, also known as COMPANION-003, evaluated CTX-009 in adult patients with metastatic colorectal cancer who had received two or three prior systemic chemotherapy regimens.1 The study is sponsored by Compass Therapeutics, reached actual primary and study completion on 2025-05-15, and had results first posted on 2026-07-28.1 Enrollment was 49 participants.1 The primary outcome was overall response rate, defined as the percentage of patients with a best overall response of complete or partial response.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.